Anmeldung erfolgt in Kürze...
Details werden geladen...
DBV Technologies to Present New Positive Data from VITESSE Study and Preview Recently Initiated THRIVE Study at the EAACI Congress 2026 | The Manila Times
Châtillon, France, June 8, 2026
Ähnliche Seiten
DBV Technologies S.A.: DBV Technologies to Present New Positive Data from VITESSE Study and Preview Recently Initiated THRIVE Study at the EAACI Congress 2026
https://www.finanznachrichten.de/nachrichten-2026-06/68711689-dbv-technologies-s-a-dbv-technologies-to-present-new-positive-data-from-vitesse-study-and-preview-recently-initiated-thrive-study-at-the-eaaci-congr-399.htm
Vanqua Bio to Present Positive Biomarker Data from Ongoing Phase 1b Study at Upcoming Medical Conferences | The Manila Times
https://www.manilatimes.net/2026/05/19/tmt-newswire/globenewswire/vanqua-bio-to-present-positive-biomarker-data-from-ongoing-phase-1b-study-at-upcoming-medical-conferences/2347027DBV Technologies Announces First Participant Screened in THRIVE Phase 2 Study of the VIASKIN® Peanut Patch in Infants ages 6 through 12 Months with Peanut Allergy | The Manila Times
https://www.manilatimes.net/2026/06/03/tmt-newswire/globenewswire/dbv-technologies-announces-first-participant-screened-in-thrive-phase-2-study-of-the-viaskin-peanut-patch-in-infants-ages-6-through-12-months-with-peanut-allergy/2357393Pharvaris to Present Clinical Data at the EAACI Annual Congress 2026 | The Manila Times
https://www.manilatimes.net/2026/05/29/tmt-newswire/globenewswire/pharvaris-to-present-clinical-data-at-the-eaaci-annual-congress-2026/2354437Eledon Pharmaceuticals to Present New Long-Term Data from Phase 2 BESTOW Trial of Tegoprubart for the Prevention of Rejection in Kidney Transplantation at American Transplant Congress | The Manila ...
https://www.manilatimes.net/2026/05/21/tmt-newswire/globenewswire/eledon-pharmaceuticals-to-present-new-long-term-data-from-phase-2-bestow-trial-of-tegoprubart-for-the-prevention-of-rejection-in-kidney-transplantation-at-american-transplant-congress/2348640